324 related articles for article (PubMed ID: 32782768)
21. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
Qian Y; Chen Y; Li X
Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
[TBL] [Abstract][Full Text] [Related]
22. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
23. [CSF3R, ASXL1,SETBP1, JAK2 V617F and CALR mutations in chronic neutrophilic leukemia].
Cui Y; Li B; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1069-73. PubMed ID: 25543699
[TBL] [Abstract][Full Text] [Related]
24. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
25. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
[TBL] [Abstract][Full Text] [Related]
26. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
He ZP; Tian HY; Tan M; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
[TBL] [Abstract][Full Text] [Related]
27. JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.
Jekarl DW; Han SB; Kim M; Lim J; Oh EJ; Kim Y; Kim HJ; Min WS; Han K
Korean J Hematol; 2010 Mar; 45(1):46-50. PubMed ID: 21120162
[TBL] [Abstract][Full Text] [Related]
28. [BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].
Amemiya A; Ito Y; Ishibashi Y; Saito Y; Katagiri S; Suguro T; Asano M; Yoshizawa S; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2017; 58(4):298-302. PubMed ID: 28484156
[TBL] [Abstract][Full Text] [Related]
29. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
30. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
31. Atypical chronic myeloid leukemia BCR-ABL 1 negative: A case report and literature review.
Belkhair J; Raissi A; Elyahyaoui H; Ameur MA; Chakour M
Leuk Res Rep; 2019; 12():100172. PubMed ID: 31194134
[TBL] [Abstract][Full Text] [Related]
32. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.
Muramatsu H; Makishima H; Maciejewski JP
Semin Oncol; 2012 Feb; 39(1):67-73. PubMed ID: 22289493
[TBL] [Abstract][Full Text] [Related]
33. Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment.
Castellino A; Santambrogio E; Rapezzi D; Massaia M
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684141
[TBL] [Abstract][Full Text] [Related]
34.
Iaquinta G; Scalzulli E; Angeloni S; Carmosino I; Costa A; Ielo C; Passucci M; Masucci C; Martelli M; Grammatico P; Breccia M
Leuk Lymphoma; 2023 Oct; 64(10):1730-1732. PubMed ID: 37435984
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53.
Wang Q; Dai HP; Liu DD; Xie JD; Yao H; Ding ZX; Tao TT; Chen SN; Zhang R
Leuk Res Rep; 2020; 14():100229. PubMed ID: 33194542
[TBL] [Abstract][Full Text] [Related]
36. Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2
Yuan J; Song J; Chen C; Lv X; Bai J; Yang J; Zhou Y
Invest New Drugs; 2022 Dec; 40(6):1194-1205. PubMed ID: 36044173
[TBL] [Abstract][Full Text] [Related]
37. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms.
Sadigh S; Hasserjian RP; Hobbs G
Curr Opin Hematol; 2020 Mar; 27(2):122-127. PubMed ID: 31904665
[TBL] [Abstract][Full Text] [Related]
38. Molecular Pathogenesis of
Fontana D; Gambacorti-Passerini C; Piazza R
Front Oncol; 2021; 11():756348. PubMed ID: 34858828
[TBL] [Abstract][Full Text] [Related]
39. A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.
Chen D; Geyer J; Bagg A; Hasserjian R; Weinberg OK
Int J Lab Hematol; 2024 Apr; ():. PubMed ID: 38665121
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
Montalban-Bravo G; Kanagal-Shamanna R; Sasaki K; Masarova L; Naqvi K; Jabbour E; DiNardo CD; Takahashi K; Konopleva M; Pemmaraju N; Kadia TM; Ravandi F; Daver N; Borthakur G; Estrov Z; Khoury JD; Loghavi S; Soltysiak KA; Pierce S; Bueso-Ramos C; Patel KP; Verstovsek S; Kantarjian HM; Bose P; Garcia-Manero G
Cancer; 2021 Sep; 127(17):3113-3124. PubMed ID: 33914911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
